Idiopathic inflammatory bowel disease (IBD) predominantly includes ulcerative colitis and Crohn's disease. The pathogenesis of IBD is complex and not completely understood. MicroRNAs belong to a class of noncoding small RNAs that post-transcriptionally regulate gene expression. Unique microRNA expression profiles have been explored in IBD. In this review, we focus on the unique microRNA expression pattern in both tissue and peripheral blood from IBD patients and emphasize the potential diagnostic and therapeutic applications. The discovery of microRNAs has contributed to our understanding of IBD pathogenesis and might lead to clinical advance in new therapeutics.
INTRODUCTION
Idiopathic inflammatory bowel disease (IBD) predo minantly includes ulcerative colitis (UC) and Crohn's disease (CD), which is a chronic and recurrent inflammatory disorder primarily involving the gastrointestinal tract. The pathogenesis of IBD is multifactorial and not completely understood, but genetic, epigenetic, infec tious, physiological, and immunological factors may all play important roles in the genesis and progression of the diseases [13] . So far, IBD is generally accepted as a complicated consequence attributable to inadequate immunological responses to luminal factors in gene tically predisposed subjects.
MicroRNAs are encoded within the genomes of a wide variety of eukaryotes, including more than 700 different microRNA genes in the human genome [4, 5] . MicroRNAs are evolutionarily conserved, single stranded noncoding RNA molecules of 1924 nucle otides, which represent a class of regulatory RNAs that decrease stability and suppress gene expression at a posttranscriptional level. MicroRNAs concurrently modulate the expression levels of dozens or more distinct messenger RNA (mRNA) targets. Alternatively, any given mRNA sequence may be targeted by several different microRNAs [46] . To date, they have been predicted to target and control the expression of at least 30% of the entire mammalian genome [7] . Since their discovery in 1933, microRNAs have been found to be involved in multiple pathophysiological networks [8, 9] and in the pathogenesis of a broadspectrum of human diseases, including cancer and inflammation [1015] . Given their potential as therapeutic targets, microRNAs have drawn a lot of attention recently.
Knowledge of microRNA in IBD has accumulated in the past seven years and has indicated that microRNAs play critical roles in the pathogenesis of chronic inflam mation and oncogenic transformation. Herein, the review focuses on the current understanding of micro RNA as biomarkers of pathogenesis and potential therapeutic implication in IBD.
DYSREGULATED MICRORNAS IN IBD
Multiple studies have demonstrated distinct microRNA expression profiles in tissue and peripheral blood of IBD patients. Many studies have been conducted on tissue and serum of patients with active or inactive IBD in an attempt to identify biomarkers and drivers of pathogenesis.
Aberrant microRNA profiles in mucosal tissue of UC
Since 2008, dysregulated microRNAs have been identified by examining inflamed or uninflamed colonic tissue in UC patients [1625] . As listed in Table  1, comparing to normal healthy controls aberrantly  elevated microRNAs have been found including miR7,  miR16, miR20b, miR21, miR23a, miR24, miR29a,   miR29b, miR31, miR98, miR125b1*, miR126,  miR126*, miR1273p, miR135b, miR146a,  miR150, miR155, miR195, miR196a, miR206,  miR223, miR3243p, miR375, miR422b, miR548a 3p, miR650, miR663, miRlet7e*, and miRlet7f. The decreased microRNAs include miR143, miR145, miR1885p, miR192, miR194b, miR196b, miR215, miR216b, miR320a, miR346, miR375, miR489, miR548e, miR559, and miR630.
Given the variable anatomic location of colonic tissue, the diverse inflammatory status (either inflamed or uninflamed with or without treatment), the different cohorts of healthy control and analytical systems, it is not surprising that the findings are not consistent among researchers. However, three microRNA candidates, miR21 [1618, 24] , miR29a [16, 19] and miR31 [19, 23] , have been found aberrantly elevated by at least two independent groups.
Aberrant microRNA profiles in mucosal tissue of CD
As shown in Table 2 , distinct microRNA expression profiles have also been studied in patients with CD [19, 23, 2529] . MiR9, miR9*, miR16, miR21, miR22, miR23b, miR26a, miR29b, miR29c, miR30a, miR30b, miR30c, miR31, miR34c5p, miR106a, miR126, miR126*, miR1273p, miR130a, miR 133b, miR141, miR146a, miR146b5p, miR150, miR155, miR181c, miR191, miR196, miR196a, miR206, miR223, miR3243p, miR375, miR594 and miR663 have been found significantly increased comparing to the normal controls [19, 23, 26, 28, 29] . The decreased microRNAs include miR7, miR18a*, miR 19b, miR1403p, miR194b, miR216b, miR548e, miR559, miR629, miR629*, and miRlet7b [23, 27, 30] . Among them, miR21 [19, 26] , miR31 [19, 23, 29] , miR 106a [19, 26] , miR146a [19, 23] , and miR223 [19, 26] have been found dysregulated by at least two independent groups.
Aberrant microRNA in peripheral blood of UC
As summarized in Table 3 , microRNA expression is also altered in the peripheral blood in patients with UC [24, 25, 3134] . In studies examining microRNAs in peripheral blood mononuclear cells of patients with either active or inactive UC, miR15b, miR16, miR 19a, miR20b*, miR21, miR22, miR24, miR27a, miR27a*, miR283p, miR285p, miR29a, miR30e, miR31, miR92a1*, miR93, miR103, miR1032, miR1032*, miR128, miR138, miR1403p, miR 1425p, miR143*, miR146a3p, miR150*, miR 1515p, miR155, miR181b, miR1885p, miR196b, miR199a3p, miR199a5p, miR221, miR223, miR 3303p, miR340*, miR345, miR3623p, miR362 5p, miR374b, miR378, miR378*, miR422a, miR 4235p, miR500, miR5015p, miR5323p, miR 5325p, miR550*, miR598, miR720, miR760, miR7693p, miR7695p, miR874, miR941, miR1271, miR1274b, miR1296, miRlet7d, miR let7e, miRlet7g, miRlet7i*, and miRplusE1271 are increasingly expressed comparing to the normal population [24, 25, 3134] . The decreased profiles include miR150 and miR505* comparing to the normal controls [25, 31, 33] . Among them, nine microRNAs, miR21 [24, 32] , miR 285p [31, 32] , miR1515p [31, 32] , miR199a5p [31, 32] , miR345 [25, 34] , miR3623p [31, 33] , miR505* [31, 33] , miR532 3p [31, 33] and miR5325p [25, 34] , have been recognized by at least two independent groups.
Aberrant microRNA in peripheral blood of CD
As listed in Table 4 , altered microRNA expression profiles are also found in the peripheral blood in patients with CD [25, 3133] . Compared to healthy controls, the increased microRNA profiles in the serum of patients with active CD include miR16, miR20a, miR21, miR23a, miR27a*, miR29a, miR30e, miR93, miR106a, miR107, miR126, miR140, miR 1403p, miR1405p, miR1885p, miR191, miR192, miR195, miR199a5p, miR200c, miR340*, miR362 3p, miR484, miR5323p, miR877, miRplusE1271, and miRlet7b. The significantly decreased microRNAs consist of miR18a, miR128, miR1405p, miR145, miR149*, miR877, and miRplusF1065.
Among them, six microRNAs, including miR16 [25, 32, 33] , miR106a [32, 33] , miR195 [25, 33] , miR199a5p [31, 32] , miR 3623p [31, 32] , and miR5323p [31, 32] , have been found by at least two independent groups.
MicroRNA as a differential biomarker to distinguish between UC and CD
As shown in Table 5 , studies have shown that micro RNAs are differentially expressed between UC and CD [19, 31, 35] . [17] , 2010
Sigmoid, n = 12 Healthy Increased: miR-21 and 126 Feng et al [18] , 2012
Colon, nonspecific, n = 10 Healthy Decreased: miR-188-5p, 215, 320a and 346 Fasseu et al [19] , 2010
Increased: miR-7, 31, 135b and 223 Colon, nonspecific, n = 5
Healthy Increased: miR-150 Bian et al [20] , 2011
Colon, nonspecific, n = 8 Healthy Decreased: miR-143 and 145 Pekow et al [21] , 2012
Colon, nonspecific, n = 20 Healthy Increased: miR-20b, 98 and let-7e* Coskun et al [22] , 2013
Active or inactive UC Colon, distalmost, n = 10 Healthy Decreased: miR-194b, 216b, 548e and 559 Lin et al [23] , 2014
Increased: miR-31, 146a, 206 and 663 Inactive UC Sigmoid, n = 15 Healthy Increased: miR-16, 23a, 24, 29a, 375 and 422b Wu et al [16] , 2008
Colon, nonspecific, n = 8 Healthy Decreased: miR-188-5p, 215, 320a and 346 Fasseu et al [19] , 2010
Increased: miR-29a, 29b, 126*, 127-3p, 196a and 324-3p Colon, nonspecific, n = 19
Healthy Increased: miR-20b and 125b-1* Coskun et al [22] , 2013
Unknown Colon, nonspecific, n = 15 Healthy Increased: miR- 21 Yang et al [24] , 2013
Active UC Colon, nonspecific, n = 20 Inactive UC Increased: miR-98 Coskun et al [22] , 2013
Colon, left or sigmoid, n = 9 Inactive UC Decreased: miR-196b, 489 and 630 Iborra et al [25] , 2013
Increased: miR-548a-3p and 650
UC: Ulcerative colitis.
Status
Tissue type Control Aberrant microRNA expression Ref.
Active CD Sigmoid, n = 5 Healthy Decreased: miR-19b and 629 Wu et al [26] , 2010
Increased: miR-23b, 106a and 191 Terminal ileum, n = 6 Healthy Increased: miR-16, 21, 223, and 594 Wu et al [26] , 2010
Colon, nonspecific, n = 16 Healthy Increased: miR-9, 21, 22, 26a, 29b, 29c, 30b, 31, 34c-5p, 106a, 126, 126*, 127-3p, 130a, 133b, 146a, 146b-5p, 150, 155, 181c, 196a, 324-3p and 375
Fasseu et al [19] , 2010
Colon, nonspecific, n = 8 Healthy Decreased: miR-7 Nguyen et al [27] , 2010
Colon, nonspecific, n = 120 Healthy Increased: miR-196 Brest et al [28] , 2011
Active and inactive CD Colon, nonspecific, n = 15 Healthy Increased: miR-31 and 141 Huang et al [29] , 2015
Colon, distalmost, n = 9 Healthy Decreased: miR-194b, 216b, 548e and 559 Increased: miR-31, 146a, 206 and 663
Lin et al [23] , 2014
Inactive CD Colon, nonspecific, n = 8 Healthy Increased: miR-9*, 21, 22, 26a, 29b, 29c, 30a*, 30b, 30c, 31, 34c-5p, 106a, 126*, 127-3p, 133b, 146a, 146b-5p, 150, 155, 196a, 223 and 324-3p
Active CD Colon, left or sigmoid, n = 9 Inactive CD Decreased: miR-18a*, 140-3p, 629* and let-7b Increased: miR-328, 422a and 885-5p
Iborra et al [25] , 2013 CD: Crohn's disease; UC: Ulcerative colitis.
Fisher K et al . microRNA in inflammatory bowel disease Table 5 Differential microRNA expression between ulcerative colitis and Crohn's disease Table 4 Aberrant microRNA expression in human peripheral blood in Crohn's disease Table 3 Aberrant microRNA expression in human peripheral blood in ulcerative colitis miR19b, miR23b, miR100a3p, miR100b5p, miR 106a, miR150, miR191, miR196b, miR223, miR 320a, and miR629 [19, 35] . Wu and colleagues found three microRNAs (miR31803p, miRplusE1035 and miRplusF1159) differentially expressed in the peripheral blood between UC and CD [31] . Although at least two groups have developed tissue microRNA panels that attempted to delineate between UC and CD, there is little overlap. Importantly, these studies vary in the activity status of IBD during sampling, which may explain the differences seen by independent groups.
MicroRNA in indeterminate IBD
A diagnosis of idiopathic IBD requires comprehensive analysis of clinical, radiographic, endoscopic, surgical, and histologic data. While most cases of IBD can be specifically classified as either UC or CD, 5%10% of IBD patients bear equivocal features, falling into the category of indeterminate colitis [3638] . The ability to better classify cases of indeterminate colitis would allow for better clinical and surgical management of these patients, especially regarding the choice of pouch procedure.
In a study by Lin and colleagues, a panel of miR Active UC Peripheral blood, n = 13 Healthy Decreased: miR-505* Wu et al [31] , 2011
Increased: miR-28-5p, 103-2*,151-5p, 199a-5p, 340*, 362-3p, 532-3p and plus-E1271 Peripheral blood, n = 88 Healthy Increased: miR-16, 21, 28-5p, 151-5p, 155 and 199a-5p
Paraskevi et al [32] , 2012 Iborra et al [25] , 2013
Inactive UC Peripheral blood, n = 13 Healthy Decreased: miR-505* Zahm et al [33] , 2011 Increased: miR-103-2, 362-3p and 532-3p Inactive UC Peripheral blood, n = 10 Healthy Decreased: miR-505* Wu et al [31] , 2011 [34] , 2012
Peripheral blood, n = 15 Healthy Increased: miR-21 Yang et al [24] , 2013
UC: Ulcerative colitis. Paraskevi et al [32] , 2012
Status
Active and inactive CD Peripheral blood, n = 18 Healthy Decreased: miR-877 Iborra et al [25] , 2013
Increased: miR-16, 27a*, 140-3p, 140-5p and 195 Inactive CD Peripheral blood, n = 5 Healthy Decreased: miR-149* Wu et al [31] , 2011
Increased: miR-340* Active CD Peripheral blood, n = 9 Inactive CD Decreased: miR-18a, 128, 140-5p and 145 Iborra et al [25] , 2013
Increased: miR-188-5p and 877 CD: Crohn's disease; UC: Ulcerative colitis.
Inactive UC Colon, nonspecific, n = 8 Inactive CD Decreased: miR-100a-3p, 100b-5p, 150, 196b, 223 and 320a Fasseu et al [19] , 2010
Active or inactive UC Colon, distalmost, n = 12 Active or Inactive CD Increased: miR-19b, 23b, 106a, 191 and 629
Lin et al [35] , 2013
Active UC Peripheral blood, n = 13 Active CD Increased: miR-3180-3p, plus-E1035 and plus-F1159 Wu et al [31] , 2011
CD: Crohn's disease; UC: Ulcerative colitis.
19b, miR23b, miR106a, miR191 and miR629, was evaluated in 16 patients with clinical diagnosis of indeterminate colitis. They found that 15 patients demonstrated UClike and one CDlike microRNA expression patterns [35] . They concluded that microRNA expression pattern in indeterminate colitis are far more similar to those of UC than CD. The study of microRNA expression pattern in indeterminate colitis provides molecular evidence indicating that most indeterminate colitis are probably UC, rather than CD, which is similar to the data from longterm clinical follow ups. Molecular testing using microRNA as promising markers to improve the classification of indeterminate IBD has the considerable advantage of being testable at the time of colectomy for improved pouch surgery selection. Before being used as a clinically validate test, clinical validation in large samples of indeterminate colitis patients, especially with correlation to pouch prognosis, is a necessity.
MICRORNA AS A POTENTIAL DRIVER OF PATHOGENESIS
Despite the heterogeneity of microRNAs identified as deregulated in IBD, a few microRNAs confirm in multiple studies and may represent causative agents in disease development. Here we focus on the microRNA with the best evidence as driver of pathogenesis.
MiR-21 potentiates disease severity in IBD
As discussed above, miR21 has been identified as being upregulated in active UC and CD, consistent with its possible role in the pathogenesis of IBD [1618, 24] .
In vitro experiments have shown that the genetic deletion of DNMT1 and DNMT3b caused dysregulation of approximately 10% of microRNAs, demonstrating tight regulation by DNA methylation [39] . The use of microarray and confirmatory pyrosequencing have shown the miR21 locus is hypomethylated, and therefore overexpressed, in samples of peripheral blood in active CD in pediatric and adult patients [40] . To determine if miR21 was a potential driver of IBD pathogenesis, a miR21 knockout mouse model was developed and treated with dextran sodium sulphate (DSS) to induce a chronic colitis model with an elevation of tumor necrosis factor alpha (TNFα) that mimics human IBD [41] . In wild type mice, the addition of DSS caused a significant increase in miR21 levels, a dramatic reduction in weight, and significant mortality while the miR21 knockout mice were resistant to these negative effects, which supports a role of miR21 in IBD pathogenesis.
The pathogenic effects of miR21 overexpressing are thought to be mediated through at least 3 separate mechanisms. First, miR21 is thought to cause increased intestinal permeability, a factor thought to initiate IBD. At baseline, no difference in intestinal permeability was seen between wild type and miR21 knockout mice [41] . After treatment with DSS, intestinal permeability was greater in wild type mice than that of miR21 knockout strain. Secondly, miR21 is pro apoptotic. Although the mechanism has not been elucidated, miR21 knockout mice treated with DSS had less intestinal epithelial cell apoptosis [41] . Prevention of epithelial cell apoptosis may help maintain the epithelial cell barrier and limit inflammation and disease progression. Thirdly, interstitial fibrosis is a hallmark of IBD and miR21 has been associated with fibrosis in multiple disease models. Mouse models of renal fibrosis have shown that cellular injury leads to increased levels of TNFα and subsequent induction of miR21 [42] . Inhibition of miR21 prevented fibrosis, presumably through preventing the recruitment of profibrotic inflammatory cells [42] . Increased serum levels of miR21 were seen in humans with idiopathic pulmonary fibrosis and may serve as a noninvasive biomarker for disease progression [43] . Analysis of serum and hepatic tissue from patients with cirrhosis has also shown that increased miR21 levels are associated with levels of fibrosis [44] . Although miR21 has not been experimentally linked to fibrosis in IBD yet, its role deserves further study. Interestingly, miR21 expression was found to be high in IBD associated dysplasia suggesting that its expression is maintained throughout the development of dysplasia and carcinogenesis, but more controlled studies are needed to define its role [45] .
MICRORNA AS A POTENTIAL BIOMARKER FOR CARCINOGENESIS
Longstanding IBD is a wellknown risk factor for colorectal cancer, although mechanisms of carcino genesis are poorly unknown [46, 47] . Studies have shown that the risk of IBDassociated colon cancer is related to the extent of the disease, severity of inflammation, and duration [4850] . With chronic inflammation, colonic epithelium undergoes a transformation from inflamed, but not dysplastic to progressively dysplastic, and eventually to adenocarcinoma. Colonoscopies with surveillance biopsies for IBDassociated dysplasia are used to help guide surgical timing of colectomies. Although histologic examination can reproducibly identify dysplasia, IBDassociated dysplasia cannot be distinguished from sporadic dysplasia based on histologic appearance alone. Histologic examination of IBDassociated adenocarcinomas has characteristic features and demographics which may indicate a specific pathway to carcinogenesis [51] . Molecular alterations have been shown to lead to this histological progression [5258] . Previous studies have demonstrated molecular abnormalities in normalappearing non dysplastic mucosa from patients with UC who had a remote dysplastic lesion [5557, 5961] . Aneuploidy, chromosomal alterations, p53 mutation, loss of hetero zygosity, and chromosome instability are present in
Fisher K et al . microRNA in inflammatory bowel disease normalappearing mucosa before the development of dysplasia [5557, 5961] . Studies of microRNAs may elucidate distinct pathways that may help reliably identified IBD associated dysplasia and subsequent carcinogenesis. Recent studies demonstrate that microRNAs are largely involved in oncogenesis via their regulation of tumor suppressors and oncogenes [62] . In a study by Olaru et al [63] , microRNA arrays were performed on tissue from eight patients with IBDassociated dysplasia. Twenty two microRNAs (miR31, miR31*, miR96, miR135b, miR141, miR183, miR192, miR192*, miR194, miR194*, miR200a, miR 200a*, miR200b, miR200b*, miR200c, miR203, miR215, miR224, miR375, miR424*, miR429, and miR552) were significantly upregulated and 10 microRNAs (miR122, miR1395p, miR1423p, miR 146b5p, miR155, miR223, miR4902p, miR501 5p, miR892b, and miR1288) were downregulated in dysplastic epithelium compared to the nondysplastic inflamed tissue.
MiR-31 identifies IBD-associated dysplasia
MiR31 is upregulated in UC and CD, but not in other nonIBD colitis, such as microscopic colitis, that have no association with dysplasia or malignancy [64] . As early as 2007, miR31 was found to be upregulated in sporadic colorectal adenocarcinomas [6567] . However, the role of miR31 in IBDassociated dysplasia or malignancy has only recently been examined. An assessment of the baseline miR31 expression in normal tissue regardless the different anatomic locations of the colon allows for comparison of all colon specimens equally [63] . In addition, no difference of miR31 expression level was seen between IBD associated dysplasia and IBDassociated carcinomas. Importantly, the levels of miR31 were found 11fold higher in IBDassociated dysplasia or carcinoma when compared to that of IBD tissue without dysplasia [63] . Although in a smaller study set, these findings were not replicated and a link between microRNAs and p53 dysregulation was indicated [68] Taken together, these findings suggest that miR31 alteration might happen early in carcinogenesis and may be used a biomarker for IBDassociated dysplasia or malignancy.
MICRORNA AS POTENTIAL THERAPEUTIC TARGETS FOR IBD
Understanding the underlying mechanisms that regulate gene expression and the complex interplay of factors is essential to develop novel therapeutics in IBD. The posttranscriptional regulation of gene expression is unique and is becoming increasingly important. The ability of microRNAs to target multiple genes and biological signaling pathways has drawn great attention in potential clinical utility as innovative therapeutic agents in treatment. Antisense oligo nucleotides complementary to microRNAs, namely antimicroRNA oligonucleotides, can target specific microRNAs abolishing their function in in vitro cultured cells, or in vivo in animal models. For example in the achievement of cancer research, recent accumulating preclinical studies have shown the feasibility of slowing tumor progression by either overexpressing tumor suppressive microRNAs, or by neutralizing the activities of oncogenic microRNAs in cell or animal based cancer models [6972] . In addition, a number of clinical drugs have shown to modulate the microRNA expression as anticancer effect in vitro [73, 74] . Particularly in the field of IBD, the mechanisms to modify microRNAs that might activate or inactivate pathways required for the inflammation progress are worth investigating. Potential therapeutic application targeted on microRNA is to block inflammatory progression to improve sensitivity to conventional therapies. The pharmacologic targeted tissue delivery consists of two general strategies: (1) antisense oligonucleotides complementary to specific mature microRNAs to inactivate the overexpressed pro inflammatory process; and (2) to replace the expression of suppressive microRNAs.
To date, no therapeutic manipulation of microRNAs in IBD has been published in either cell lines or animal models yet. Although recent study has shown that inhibition of miR21, a promising pathogenetic driver in IBD, slows the proliferation and progression in a nasopharyngeal carcinoma cell line [75] . The similar approach is expected to be tested in IBD cell line or animal model. Although side effects are another essential issue to be considered before an effective drug enters the markets, we can't help speculating that a new therapeutic concept, targeted microRNA drug for IBD, maybe emerges in the near future.
DILEMMAS
During the past 7 years, the identification of microRNA in IBD has broadened our knowledge. However, the lack of a standardized approach often leads to inconsistent or even conflicting results.
The nomenclature for microRNA has continued to evolve since its discovery in 1993 [8, 9] . MicroRNAs were named in the order they were discovered, leading to identical microRNAs being given different names by different groups. As the microRNA field continues to expand, significant efforts have been made to clarify nomenclature using a unified system. Recent data added from deep genome sequencing has pushed the number of annotated microRNAs to roughly 1900 in the most recently nomenclature database, miRBase version 21 [76] . The complicated historical nomenclature of microRNA makes literature evaluation difficult and diligent effort to confirm sequence identity of each in the literature must be made.
One of the most commonly encountered problems is when we attempt to verify microRNA's role in IBD pathogenesis. Recent developments in microarrays have led to numerous attempts to identify microRNAs associated with a diverse set of disease processes. Despite the ability of candidate microRNAs to be validated by additional RTPCR, there has been little reproducibility between groups. Differences in samples obtained from various anatomic locations, treatment regimens, and activity level of disease may account for discrepancies seen between studies. Additionally, microRNAs with the same sequence identity are given modifiers in their name based on their location within the genome. Most techniques do not distinguish microRNAs that have the same sequence but at different locations in the genome [76] . A more clear understanding of the genetic loci associated with micro RNAs can provide insight into how they are regulated and become deregulated in pathogenesis.
CONCLUSION
In summary, the accumulating knowledge of microRNA has significantly expanded our understanding of the pathogenesis of IBD and has demonstrated the usefulness of microRNAs as biomarkers with emerging clinical utility and the potential for personalized therapies.
